The market research firm credits GLP-1 demand for a projected 9.5% yearly growth rate, with Asia Pacific expected to grow fastest.
Recap by typeshit. Full story at Yahoo Finance.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
UK regulators and police entered an industrial unit on 14 October, with a warning for anyone who got their jab outside a pharmacy.
He points to the trial's reported 20% drop in cardiovascular events among people without diabetes and what it could mean for prevention.
Loading…